We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lifeline Sci. S | LSE:LSI | London | Ordinary Share | COM SHS USD0.01 (REG S) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 137.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLSI
RNS Number : 8361Y
Lifeline Scientific, Inc
28 February 2013
27 February 2013
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Admission of shares and TVR
Lifeline Scientific, the medical technology company, has transferred 13,213 common shares of $0.01 each from Regulation S restricted stock to unrestricted stock and admission is expected to occur on 5 March 2013.
Lifeline has 19,424,959 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 19,424,959.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FSA's Disclosure and Transparency Rules.
Following this transfer, 6,717,805 common shares remain subject to Regulation S restrictions and are held in certificated form only. These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.
The remaining 12,707,154 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.
Enquiries:
Lifeline Scientific, Inc. +1 847 824 2436 Lisa Kieres, CFO Seymour Pierce +44 (0)20 7107 8000 Mark Percy (Corporate Finance) David Banks (Corporate Broking) FTI Consulting +44 (0)20 7831 3113 Simon Conway / John Dineen
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 135 leading transplant programmes in 23 countries worldwide, LifePorts have successfully preserved over 38,000 kidneys intended for clinical transplant. The product provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimise damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, LifePort records data on temperature, flow rate, vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. LifePort is the only system with clinical outcomes data produced from an independent, prospective, randomised, statistically powered, multi-centre clinical trial. Study results have been widely published in scientific journals, including the New England Journal of Medicine. Data indicates that patients receiving LifePort preserved kidneys experienced significant reduction in the incidence and duration of delayed graft function and increased graft survival at 1-year and 3-years post transplant. LifePort has also been recognised for its design and engineering. It has received prominent awards for design excellence from the medical device industry, has been selected for exhibition at the Smithsonian Cooper-Hewitt, National Design Museum and is part of the permanent Collection of The Museum of Modern Art (MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the FDA cleared, CE marked and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart, and lung are in late stage pre-clinical development.
see www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISMMGZZNNRGFZM
1 Year Lifeline Sci. S Chart |
1 Month Lifeline Sci. S Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions